

1 **Title:** Post-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness –  
2 data from 2023

3 **Authors:** Hannah Charles (0000-0002-3229-6198), Katie Thorley (0000-0003-4322-2909),  
4 Charlie Turner, Kirsty F. Bennet (0000-0002-4730-4779), Nick Andrews, Marta Bertran,  
5 Sema Mandal (0000-0003-3379-3118), Gayatri Amirthalingam, Mary E. Ramsay, Hamish  
6 Mohammed (0000-0002-2060-7286), Katy Sinka (0000-0001-8596-0649)

7 **Affiliation:** UK Health Security Agency, London, UK

8 **Corresponding author:** Hannah Charles, UK Health Security Agency, 61 Colindale Avenue,  
9 London, NW9 5EQ, UK; email: [hannah.charles@ukhsa.gov.uk](mailto:hannah.charles@ukhsa.gov.uk)

10

11 **Keywords:** [mpox](#), [surveillance](#), [epidemiology](#), [men who have sex with men](#), [GBMSM](#),  
12 [vaccine effectiveness](#)

13

#### 14 **Abstract**

15 England, like other countries that experienced a large outbreak of emergent mpox in 2022,  
16 continued to record cases during 2023 at a low but steady frequency. Comprehensive  
17 national surveillance shows that cases continue to occur primarily among gay, bisexual and  
18 other men who have sex with men mostly in London. Of 137 cases in 2023, around half were  
19 acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven  
20 people required hospital care. High vaccination uptake, during 2022, has provided good  
21 coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness  
22 of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.

23

24 **Ethical statement:** This analysis was undertaken for health protection purposes under  
25 permissions granted to UKHSA to collect and process confidential patient data under  
26 Regulation 3 of The Health Service (Control of Patient Information) Regulations 2020 and  
27 Section 251 of the National Health Service Act 2006.

28 **Funding statement:** No external funding was received for this work.

29 **Acknowledgements:** We would like to thank NHS England for their collection and sharing  
30 of vaccination data for the mpox vaccination programme and sexual health services for  
31 delivering the vaccines. We would also like to thank the UKHSA Health Protection Teams  
32 for collecting epidemiological information during public health management of cases.

33 **Conflict of interest:** None

34 **Authors' contributions:** HC led the epidemiological analysis and drafted the manuscript.  
35 The epidemiological data analysis was validated by KT and KFB. NA led the vaccine

36 effectiveness analysis. All co-authors contributed to interpretation of the findings and to  
37 revision of the manuscript.

38

## 39 Introduction

40 In May 2022, an international outbreak of mpox was identified, primarily affecting highly  
41 interconnected sexual networks of gay, bisexual and other men who have sex with men  
42 (GBMSM). In England, the number of mpox cases peaked in mid-July 2022 at 350 cases per  
43 week (1), and then declined to fewer than six cases per week from November onwards (2).  
44 From June 2022, the Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN) vaccine was  
45 offered to GBMSM in England who were assessed as being at higher risk of mpox infection,  
46 including those with a recent history of multiple partners, participating in group sex or  
47 attending sex-on-premises venues (3), with the estimated vaccine effectiveness of one dose  
48 being 78% (4). Although the number of cases declined, mpox cases continued to be reported  
49 throughout 2023. Surveillance has continued to detect changes in the epidemiology and  
50 record risk factors that contribute to the ongoing occurrence of new mpox cases. This  
51 analysis summarises the epidemiology of post-peak mpox cases in 2023 in England (01  
52 January to 31 December), describes case characteristics including vaccination status,  
53 investigates if characteristics varied to those from the peak of the outbreak, and estimates the  
54 effectiveness of vaccination to protect against symptomatic disease.

55

## 56 Materials and Methods

57 Records of confirmed and highly probable mpox diagnoses reported between 01 January and  
58 31 December 2023 were extracted from the UK Health Security Agency (UKHSA) Second  
59 Generation Surveillance System (SGSS) and deduplicated using specimen and patient  
60 identifiers. A confirmed case was defined as a positive *monkeypox virus*-specific polymerase  
61 chain reaction (PCR) and a highly probable case as a positive *Orthopoxvirus* PCR (5). SGSS  
62 receives positive test results from all diagnostic laboratories in England (6). Given the initial  
63 status of mpox as a high consequence infectious disease (HCID) and ongoing status as a  
64 statutory notifiable disease (7), in addition to the World Health Organization (WHO)  
65 classifying the 2022 outbreak as a Public Health Emergency of International Concern  
66 (PHEIC) (8), the reporting of mpox diagnoses to SGSS is very likely to be complete.  
67 Additional epidemiological and behavioural information was collected by UKHSA's local

68 Health Protection Teams. Aggregate data on mpox vaccinations administered in 2022 and  
69 2023 were provided by National Health Service (NHS) England. Overall vaccine  
70 effectiveness was estimated using the screening method (9). Difference between one dose  
71 and two dose vaccine effectiveness estimates were tested by a chi-squared test at a 5%  
72 significance level.

73

## 74 Results

75 There were 137 mpox cases in the period between 01 January and 31 December 2023, 135  
76 were confirmed cases and two were highly probable. Following an initial period of low-level  
77 reporting, with nine cases in total between January and March (Week 1 to Week 13) 2023,  
78 there was an increase in the frequency of cases, with a further 128 cases between April and  
79 the end of December (Week 17 to Week 52) (Figure 1). Consistent with the outbreak overall,  
80 of the 137 mpox cases in 2023, the majority (105 out of 137; 77%) were resident in London;  
81 the remaining 32 cases were reported from the East Midlands, South East, Yorkshire and  
82 Humber, East of England, North West and South West of England.

83 Most cases identified as GBMSM (107 out of 137; 78%), an additional 21 cases were adult  
84 men without recorded information on sexual orientation and for this analysis of cases were  
85 assumed to be part of the 2022-23 global mpox outbreak, totalling 128 (out of 137; 93%).  
86 Eight cases were not considered to be part of this outbreak given information linking their  
87 infection to an mpox endemic country, these were sporadic cases distributed across the time  
88 period and consisted of heterosexual individuals and children. There was one further adult  
89 case where neither gender nor sexual orientation was reported.

90 Of the 137 cases in 2023, 64 individuals (47%) reported they did not travel outside the United  
91 Kingdom (UK) in the 21 days prior to symptom onset, indicating that they likely acquired  
92 mpox in the UK; 57 (89%) of these individuals identified as GBMSM (Table 1).

93 Fifty-three individuals (39%) reported travel outside the UK, and of these, 43 (81%)  
94 identified as GBMSM and reported travelling to countries in Europe, the Middle East, Asia  
95 Pacific and North America.

96 Over half of cases in 2023 associated with the 2022-23 global mpox outbreak were HIV  
97 negative (69 out of 128; 54%), of whom most (51 out of 69; 74%) were taking HIV pre-  
98 exposure prophylaxis (PrEP). Thirty-nine individuals (39 out of 128; 30%) reported attending

99 an event involving sexual contact with multiple partners and 24 individuals (19%) were  
100 diagnosed with a concurrent STI. One individual reported also having a previous mpox  
101 diagnosis in 2022 (Table 2).

102 Of cases associated with the 2022-23 global mpox outbreak, 52 (49%) of the 106 cases with  
103 known vaccination status were fully or partially vaccinated, of whom one case reported three  
104 doses, 29 cases received two doses and 20 cases received one dose, and 2 did not report the  
105 number of doses. Among these vaccinated cases, 20 (38%) reported attending an event  
106 involving sexual contact with multiple partners and were therefore likely to have been at  
107 higher risk of exposure to mpox. Eleven individuals were admitted to hospital due to their  
108 mpox infection (9%), nine were unvaccinated and two had unknown vaccination status.

109

#### 110 Overall vaccine effectiveness

111 Between July 2022 and December 2023, 77,543 GBMSM in England were vaccinated against  
112 mpox; 32,983 individuals with one dose and 44,560 with two. Based on an estimated eligible  
113 GBMSM denominator of 89,240 as used previously (4) this gives a coverage estimate at the  
114 end of December 2023 of 37.0% for one dose and 49.9% for two doses (86.9% one or two  
115 doses). Most vaccines had been given by March 2023 (91.0% of first doses and 75.7% of  
116 second doses).

117 Vaccine effectiveness was calculated using the screening method, as previously described  
118 (4). For the primary analysis, the eligible GBMSM denominator was taken to be 89,240 and  
119 20% higher at 107,088 in a sensitivity analysis, similar to previous analyses (4). For the  
120 calculation of vaccine effectiveness, the proportion of GBMSM vaccinated was estimated  
121 based on matching each case to the one and two dose coverage at the time two weeks before  
122 individuals became a case, then averaging this matched coverage across cases. For the 22  
123 cases where vaccination status was unknown, it was assumed that these would be distributed  
124 among those with 0, 1 and 2 doses in the same ratio as the observed ratio for these groups, to  
125 give a corrected value.

126 Vaccine effectiveness of a single dose was estimated at 84% (Table 3) - comparable to the  
127 previous estimate of 78% (4). The vaccine effectiveness of two doses was similar to one  
128 dose, at 80% ( $p=0.40$ ). The overall vaccine effectiveness of one or two doses was 82%.

129

130

131

132 None of the vaccinated cases in 2023 were hospitalised, compared to eleven among those  
133 unvaccinated (or where vaccination status was not known). The sensitivity analysis resulted  
134 in vaccine effectiveness estimates which were markedly lower, demonstrating that the  
135 method is affected by assumptions of the size of the GBMSM population.

136

### 137 Discussion

138 The very low case numbers at the start of the 2023 were initially interpreted as the final few  
139 cases in the tail of the outbreak from 2022 (1). However, like other countries where the 2022  
140 outbreak had been substantial, cases continued to occur steadily throughout the year with an  
141 even split of imported infections and community transmission.

142 The demographic and behavioural characteristics of mpox cases in 2023 remained similar to  
143 the peak of the outbreak in 2022 (10-12) and indicate that mpox continues to circulate  
144 predominately within interconnected sexual networks of GBMSM.

145 Nearly half of the cases in England in 2023 had been vaccinated and there were more cases  
146 among those who had received two doses of MVA-BN vaccine, compared to one dose. The  
147 vaccine effectiveness, influenced by the size of the GBMSM population, was similar for one  
148 dose and two doses, with the point estimate a little higher for one dose. Considering that first  
149 doses will have been given longer ago than second doses and that two dose would be  
150 expected to confer more protection the similar VE is counter intuitive. The similar VE may  
151 reflect differences in risk behaviour in those who came forward for a second dose of vaccine  
152 as they may also be more likely to come into contact with the monkeypox virus. This  
153 phenomenon of risk compensation has been suggested with other emerging infectious  
154 diseases such as COVID-19, particularly if behaviour modification associated with  
155 vaccination status occurs (13)(14). Increased awareness of the effectiveness of the MVA-BN  
156 vaccine and associated reduction in fear of mpox since the rollout of the vaccination  
157 programme may have also played a part. Critically, the finding that there were no  
158 hospitalised cases in 2023 among vaccinated individuals provides assurance that the MVA-  
159 BN vaccine protects against severe disease, which is corroborated by a global case series

160 which found that illness among vaccinated individuals was less severe (15), and recent data  
161 from France (16).

162 The picture seen in England is consistent with reports from other high-income countries with  
163 outbreaks predominantly among GBMSM - in March 2023, reports of a cluster of mpox in  
164 France, included more vaccinated than unvaccinated individuals and in May 2023 the  
165 Chicago Department of Public Health noted that the majority of the cases reported since mid-  
166 April were among men who had received two doses of MVA-BN vaccine (17), yet a higher  
167 number of first doses had been given compared to second doses overall (18).

168 The self-reported reinfection in 2023 follows a previous case reported from 2022 (19). This  
169 finding, alongside the observed vaccine breakthrough infections, contributes to the emerging  
170 understanding of natural and vaccine induced immunity to mpox. Although the attending  
171 sexual health clinic verified that this individual had a positive mpox test in 2022 and another  
172 in 2023, it should be acknowledged that a lack of sequencing data cannot rule out persistent  
173 infection.

174 The 2023 overall experience in England was of continued low level community transmission  
175 among GBMSM, as well as imported infections, which looks set to continue. With over 20  
176 countries continuing to report mpox cases in December 2023 and the WHO assessment that  
177 the overall global risk for men who have sex with men remains moderate (20), a forecast long  
178 tail to the outbreak is likely before elimination can be achieved. This underpins the  
179 importance of continuing with active prevention through vaccination and health promotion to  
180 those at higher risk, and ongoing surveillance to better understand factors that contribute to  
181 continued transmission.

182

### 183 References

- 184 1. UK Health Security Agency. Monkeypox outbreak: technical briefing #8. 23/09/2022.  
185 Accessed 14/02/2024. Available at: [Investigation into monkeypox outbreak in England:  
186 technical briefing 8 - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/121424/Investigation-into-monkeypox-outbreak-in-England-technical-briefing-8-23-09-2022.pdf)
- 187 2. UK Health Security Agency. Mpox (monkeypox) outbreak: epidemiological overview, 6 July  
188 2023. Accessed 14/02/2024. Available at: [Mpox \(monkeypox\) outbreak: epidemiological  
189 overview, 6 July 2023 - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/121424/Mpox-monkeypox-outbreak-epidemiological-overview-6-July-2023-6-July-2023.pdf)
- 190 3. UK Health Security Agency. Mpox (monkeypox) outbreak: vaccination strategy. 21 June  
191 2022. Accessed 14/02/2024. Available at: [Mpox \(monkeypox\) outbreak: vaccination strategy  
192 - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/121424/Mpox-monkeypox-outbreak-vaccination-strategy-21-June-2022.pdf)

- 193 4. Bertran M, Andrews N, Davison C, Dugbazah B, Boateng J, Lunt R, et al. Effectiveness of  
194 one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage  
195 method: an observational study. *Lancet Infect Dis.* 2023 Jul;23(7):828-35.
- 196 5. UK Health Security Agency. Monkeypox: case definitions. 2022. Accessed 14/02/2024.  
197 Available at: [Mpx \(monkeypox\): case definitions - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/publications/monkeypox-case-definitions)
- 198 6. UK Health Security Agency. Reporting to UKHSA: a guide for diagnostic laboratories. 2023.  
199 Accessed 14/02/2024. Available at: [Reporting to UKHSA: a guide for diagnostic laboratories](https://publishing.service.gov.uk/government/publications/reporting-to-ukhsa-a-guide-for-diagnostic-laboratories)  
200  [\(publishing.service.gov.uk\)](https://publishing.service.gov.uk)
- 201 7. UK Health Security Agency. Notifiable diseases and causative organisms: how to report.  
202 2024. Accessed 14/02/2024. Available at: [Notifiable diseases and causative organisms: how](https://www.gov.uk/government/publications/notifiable-diseases-and-causative-organisms-how-to-report)  
203  [to report - GOV.UK \(www.gov.uk\)](https://www.gov.uk/government/publications/notifiable-diseases-and-causative-organisms-how-to-report)
- 204 8. World Health Organization. WHO Director-General declares the ongoing monkeypox  
205 outbreak a Public Health Emergency of International Concern. 2022. Accessed 14/02/2024.  
206 Available at: [Second meeting of the International Health Regulations \(2005\) \(IHR\)](https://www.who.int/news/item/2022-07-23-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-emergency-of-international-concern)  
207  [Emergency Committee regarding the multi-country outbreak of monkeypox \(who.int\)](https://www.who.int/news/item/2022-07-23-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-emergency-of-international-concern)
- 208 9. Flannery B, Nick Andrews N, Feikin D, Patel MK, Commentary: Estimation of vaccine  
209 effectiveness using the screening method, *International Journal of Epidemiology*, Volume 52,  
210 Issue 1, February 2023, Pages 19–21, <https://doi.org/10.1093/ije/dyac013>
- 211 10. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al. Community  
212 transmission of monkeypox in the United Kingdom, April to May 2022. *Eurosurveillance.*  
213 2022;27(22):2200422.
- 214 11. Vusirikala A, Charles H, Balasegaram S, Macdonald N, Kumar D, Barker-Burnside C, et al.  
215 Epidemiology of Early Monkeypox Virus Transmission in Sexual Networks of Gay and  
216 Bisexual Men, England, 2022. *Emerg Infect Dis.* 2022 Oct;28(10):2082-6.
- 217 12. Charles H, Prochazka M, Murray J, Sexual Health Liaison Group U, Soni S, Hadow L, et al.  
218 Surveillance of Mpox Cases Attending Sexual Health Services in England (SOMASS):  
219 design, implementation and initial findings from the SOMASS data collection tool, 2022. *Sex*  
220 *Transm Infect.* 2023 May 18.
- 221 13. Brewer NT, Cuite CL, Herrington JE, Weinstein ND. Risk compensation and vaccination: can  
222 getting vaccinated cause people to engage in risky behaviors? *Ann Behav Med.* 2007  
223 Aug;34(1):95-9. doi: 10.1007/BF02879925. PMID: 17688401.
- 224 14. Buckell, J., Jones, J., Matthews, P.C. *et al.* COVID-19 vaccination, risk-compensatory  
225 behaviours, and contacts in the UK. *Sci Rep* **13**, 8441 (2023). [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-023-34244-2)  
226 [023-34244-2](https://doi.org/10.1038/s41598-023-34244-2)
- 227 15. Hazra A, Zucker J, Bell E, Flores J, Gordon L, Mitjà O, et al. Mpox in people with past  
228 infection or a complete vaccination course: a global case series. *Lancet Infect Dis.* 2023 Sep  
229 4.
- 230 16. Sante Publique France. Monkeypox: update on the situation in France as of March 23, 2023.  
231 Accessed 14/02/2024. Available at: [Monkeypox: update on the situation in France as of 23](https://www.santepubliquefrance.fr/fr/actualites/monkeypox-mise-a-jour-sur-la-situation-en-france-le-23-mars-2023)  
232  [March 2023 | Public Health France \(santepubliquefrance.fr\)](https://www.santepubliquefrance.fr/fr/actualites/monkeypox-mise-a-jour-sur-la-situation-en-france-le-23-mars-2023)
- 233 17. Chicago Health Alert Network. RESURGENCE OF MPOX - Provider Update: May 9, 2023.  
234 Accessed 14/02/2024. Available at: [Alert Detail - HAN \(chicagohan.org\)](https://chicagohan.org/alert-detail)
- 235 18. Chicago Department of Public Health. Mpox dashboard. 2023. Accessed 14/02/2024.  
236 Available at: [City of Chicago :: Mpox Dashboard](https://www.chicago.gov/departments/public-health/monkeypox)
- 237 19. Golden J, Harryman L, Crofts M, Muir P, Donati M, Gillett S, Irish C. Case of apparent mpox  
238 reinfection. *Sex Transm Infect.* 2023 Jun;99(4):283-284. doi: 10.1136/sextrans-2022-055736.  
239 Epub 2023 Jan 27. PMID: 36707246; PMCID: PMC10313946.
- 240 20. World Health Organization. Multi-country outbreak of mpox, External situation report#31 –  
241 22 December 2023. Accessed 14/02/2024. Available at: [Multi-country outbreak of mpox,](https://www.who.int/news/item/2023-12-22-multi-country-outbreak-of-mpox-external-situation-report-31-22-december-2023)  
242  [External situation report#31 – 22 December 2023 \(who.int\)](https://www.who.int/news/item/2023-12-22-multi-country-outbreak-of-mpox-external-situation-report-31-22-december-2023)
- 243

244 **Table 1: Exposure classification of confirmed and highly probable mpox cases, by**  
245 **gender and sexual orientation, England, 01 January to 31 December 2023**

	Cases presumed acquired in the UK	Cases presumed acquired outside the UK	Country of acquisition unknown
Gender and sexual orientation	n (%)*	n (%)*	n (%)*
GBMSM	57 (89)	43 (81)	6 (30)
Non-GBMSM or unknown	7 (11)	10 (19)	14 (70)
<b>Total</b>	<b>64</b>	<b>53</b>	<b>20</b>

246 GBMSM: Gay, bisexual and other men who have sex with men

247 \* Percentages are column percentages

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262



263 **Table 2: Characteristics and risk factors of confirmed and highly probable mpox cases**  
 264 **associated with the 2022-23 global mpox outbreak, England, 01 January to 31**  
 265 **December 2023**

	n (%)
<b>HIV status</b>	
Living with HIV	13 (10)
HIV negative	69 (54)
Taking HIV PrEP*	51 (74)
Not taking PrEP*	18 (26)
Unknown	46 (36)
<b>Vaccination status</b>	
Vaccinated – ≥2 doses □	30 (23)
Vaccinated – 1 dose	20 (16)
Vaccinated – number of doses unknown	2 (2)
Unvaccinated	54 (42)
Unknown	22 (17)
<b>Hospital admission</b>	
Yes	11 (9)
No/unknown	117 (91)
<b>Reporting attending events involving multiple sexual partners</b>	
Yes	39 (30)
No/unknown	98 (70)
<b>Concurrent STI</b>	
Yes	24 (19)
No/unknown	104 (81)
<b>Previous mpox diagnosis</b>	
Yes	1 (1)
No	64 (50)
Unknown	63 (49)

266 HIV PrEP: HIV pre-exposure prophylaxis

267 Unless otherwise stated, the denominator is 128

268 \* Denominator for percentage calculations is HIV negative individuals

269 □ Includes 1 individual who reported receiving three doses

270

271

272

273

274

275

276 **Table 3: Vaccination status of mpox cases during 2023 used to estimate vaccine**  
 277 **effectiveness of one dose, two doses and one or two doses of Modified Vaccinia Ankara –**  
 278 **Bavarian Nordic (MVA-BN) vaccine using the screening method**

Doses	2023 Cases	Corrected Cases*	PCV	PPV	PPV (sensitivity**)	VE (95% CI)	VE (95% CI) (sensitivity**)
0	54	65.4	52%	16%	30%		
1	20	24.2	19%	38%	32%	84% (74-91)	65% (42-79)
2	30	36.4	29%	45%	38%	80% (69-83)	56% (31-72)
Unknown status	22						
1 or 2	50	60.6	48%	84%	70%	82% (74-88)	60% (41-73)
Total	126	126					

279 PCV = proportion of cases with the given number of doses; PPV = proportion of the  
 280 population with the given number of doses obtained by matching each case to the population  
 281 uptake 14 days prior to onset and averaging this across cases; VE = vaccine effectiveness.  
 282  
 283 \* 22 cases with unknown vaccination status distributed among 0, 1 and 2 doses. \*\* based on  
 284 the higher estimated GBMSM denominator (107,088)  
 285

**Figure 1. Confirmed and highly probable mpox cases by week of specimen date in England, 01 January to 31 December 2023**

